Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Colorectal Cancer Reports
Published in: Current Colorectal Cancer Reports 4/2017

01-08-2017 | Basic Science Foundations in Colorectal Cancer (J Roper, Section Editor)

Inflammation and Colorectal Cancer

Authors: Apple G. Long, Emma T. Lundsmith, Kathryn E. Hamilton

Published in: Current Colorectal Cancer Reports | Issue 4/2017

Login to get access

Abstract

Purpose of Review

Colorectal cancer (CRC) is the fourth most common cancer in both men and women in the USA, resulting in over 55,000 deaths annually. Environmental and genetic factors influence the development of CRC, and inflammation is a critical hallmark of cancer that may arise from a variety of factors. While patients with inflammatory bowel disease (IBD) have a higher risk of developing CRC, sporadic CRCs may engender or be potentiated by inflammation as well. In this review, we focus on recent advances in basic and translational research utilizing murine models to understand the contribution of inflammatory signaling pathways to CRC.

Recent Findings

We discuss advances in the utility of three-dimensional enteroid/colonoid/tumoroid cultures to understand immune-epithelial interactions in CRC, as well as the potential for utilizing patient-derived tumoroids for personalized therapies.

Summary

This review underscores the importance of understanding the complex molecular mechanisms underlying inflammation in sporadic CRC and highlights up-and-coming or new avenues for CRC biomarkers or therapies.
Literature
1.
2.
3.
4.
Kern SE, Redston M, Seymour AB, Caldas C, Powell SM, Kornacki S, et al. Molecular genetic profiles of colitis-associated neoplasms. Gastroenterology. 1994;107:420–8.CrossRefPubMed
5.
Friis S, Riis AH, Erichsen R, Baron JA, Sorensen HT. Low-dose aspirin or nonsteroidal anti-inflammatory drug use and colorectal cancer risk: a population-based, case-control study. Ann Intern Med. 2015;163:347–55.CrossRefPubMed
6.
Graham DM, Coyle VM, Kennedy RD, Wilson RH. Molecular subtypes and personalized therapy in metastatic colorectal cancer. Curr Colorectal Cancer Rep. 2016;12:141–50.CrossRefPubMedCentralPubMed
7.
•• Guinney J, Dienstmann R, Wang X, de Reyniès A, Schlicker A, Soneson C, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015;21:1350–6. Describes novel classification system for CRC via coalescence of six independent CRC classification systems into four consensus molecular subtypes (CMS). CrossRefPubMedCentralPubMed
8.
• Müller MF, Ibrahim AEK, Arends MJ. Molecular pathological classification of colorectal cancer. Virchows Arch. 2016;469:125–34. Evaluates molecular changes in genetic instability in CRC and describes majority of hypermutated microsatellite instability (MSI) cancers falling into consensus molecular subtype 1 (CMS1, MSI-immune). CrossRefPubMedCentralPubMed
9.
Becht E, De Reyniies A, Giraldo NA, Pilati C, Buttard B, Lacroix L, et al. Immune and stromal classification of colorectal cancer is associated with molecular subtypes and relevant for precision immunotherapy. Clin Cancer Res. 2016;22:4057–66.CrossRefPubMed
10.
Terzić J, Grivennikov S, Karin E, Karin M. Inflammation and colon cancer. Gastroenterology 2010;138:2101–14.
11.
12.
Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313:1960–4.CrossRefPubMed
13.
Lasry A, Zinger A, Ben-neriah Y. Review Inflammatory networks underlying colorectal cancer. Nat Immunol. 2016;17:230–40.
14.
•• Grivennikov SI, Wang K, Mucida D, Stewart CA, Schnabl B, Jauch D, et al. Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature. 2012;491:254–8. Demonstrates role of IL-23 in eliciting Th17 pro-tumoriencic responses. PubMedCentralPubMed
15.
Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, Nakaya R. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology. 1990;98:694–702.CrossRefPubMed
16.
Cooper HS, Murthy SN, Shah RS, Sedergran DJ. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Investig. 1993;69:238–49.PubMed
17.
Tanaka T, Kohno H, Suzuki R, Yamada Y, Sugie S, Mori H. A novel inflammation-related mouse colon carcinogenesis model induced by azoxymethane and dextran sodium sulfate. Cancer Sci. 2003;94:965–73.CrossRefPubMed
18.
Maloy KJ, Salaun L, Cahill R, Dougan G, Saunders NJ, Powrie F. CD4 + CD25 + T R cells suppress innate immune pathology through cytokine-dependent mechanisms. J Exp Med. 2003;197:111–9.CrossRefPubMedCentralPubMed
19.
Kirchberger S, Royston DJ, Boulard O, Thornton E, Franchini F, Szabady RL, et al. Innate lymphoid cells sustain colon cancer through production of interleukin-22 in a mouse model. J Exp Med. 2013;210:917–31.CrossRefPubMedCentralPubMed
20.
Berg DJ, Davidson N, Kühn R, Müller W, Menon S, Holland G, et al. Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4 ϩ TH1-like responses. J Clin Invest. 1996;98(4):1010–20.CrossRefPubMedCentralPubMed
21.
Davidson NJ, Leach MW, Fort MM, Thompson-snipes L, Kiihnfl R, Mi W, et al. T helper cell 1-type C D 4 + T cells, but not B cells mediate colitis in interleukin 10-deficient mice. J Exp Med 1996;184:241–51.
22.
Su L, Kinzler KW, Vogelstein B, Preisinger AC, Moser R, Luongo C, et al. Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC Gene Published by: American Association for the Advancement of Science Stable URL: http://​www.​jstor.​org/​stable/​2876870 Multiple intestinal neoplasia caused by a mutation. 1992;256:668–70.
23.
Gounari F, Chang R, Cowan J, Guo Z, Dose M, Gounaris E, et al. Loss of adenomatous polyposis coli gene function disrupts thymic development. Nat Immunol. 2005;6:800–9.CrossRefPubMedCentralPubMed
24.
Cheung AF, Carter AM, Kostova KK, Woodruff JF, Crowley D, Bronson RT, et al. Complete deletion of Apc results in severe polyposis in mice. Oncogene. 2010;29:1857–64.CrossRefPubMed
25.
Smits R, Van Oordt WVH, Luz A, Zurcher C, Jagmohan-Changur S, Breukel C, et al. Apc1638N: a mouse model for familial adenomatous polyposis-associated desmoid tumors and cutaneous cysts. Gastroenterology. 1998;114:275–83.CrossRefPubMed
26.
Hinoi T, Akyol A, Theisen BK, Ferguson DO, Greenson JK, Williams BO, et al. Mouse model of colonic adenoma-carcinoma progression based on somatic Apc inactivation. Cancer Res. 2007;67:9721–30.CrossRefPubMed
27.
Chaudhry A, Samstein RM, Treuting P, Liang Y, Pils MC, Heinrich J, et al. Interleukin-10 signaling in regulatory T cells is required for suppression of Th17 cell-mediated inflammation. Immunity. 2011;34(4):566–78.CrossRefPubMedCentralPubMed
28.
Dennis KL, Saadalla A, Blatner NR, Wang S, Venkateswaran V, Gounari F, et al. T-cell expression of IL10 is essential for tumor immune surveillance in the small intestine. Cancer Immunol Res. 2015;3:806–15.CrossRefPubMedCentralPubMed
29.
•• Dennis KL, Wang Y, Blatner NR, Wang S, Saadalla A, Trudeau E, et al. Adenomatous polyps are driven by microbe-instigated focal in flammation and are controlled by IL-10-producing T cells. Cancer Res. 2013;73(19):5905–13. Described influence of microbiota on eliciting IL-10 response and requirement of IL-10 to donwregulate tumorigenesis. CrossRefPubMedCentralPubMed
30.
Wang L, Wang Y, Song Z, Chu J, Qu X. Deficiency of interferon-gamma or its receptor promotes colorectal cancer development. J Interf Cytokine Res. 2015;35:273–80.
31.
Tjandra SS, Hsu C, Goh I, Gurung A, Poon R, Nadesan P, et al. IFN-Beta signaling positively regulates tumorigenesis in aggressive fibromatosis, potentially by modulating mesenchymal progenitors. Cancer Res. 2007;67:7124–31.CrossRefPubMed
32.
•• Katlinski KV, Gui J, Katlinskaya YV, Koumenis C, Rui H, Fuchs SY. Inactivation of interferon receptor promotes the establishment of immune privileged tumor article inactivation of interferon receptor promotes the establishment of immune privileged tumor microenvironment. Cancer Cell. 2017;31:194–207. Demonstrates that tumor cells can downregulate type I interferon receptors to reduce effectiveness of PD-1 blockade. Stabilization of INFRa decreases tumor size and incidence. CrossRefPubMed
33.
Song X, Gao H, Lin Y, Yao Y, Zhu S, Wang J, et al. Alterations in the microbiota drive interleukin-17C production from intestinal epithelial cells to promote tumorigenesis. Immunity. 2013;40:140–52.CrossRef
34.
Richter C, Herrero San Juan M, Weigmann B, Bergis D, Dauber K, Muders MH, et al. Defective IL-23/IL-17 Axis protects p47phox−/− mice from colon cancer. Front Immunol. 2017;8:1–10.CrossRef
35.
Popivanova BK, Kitamura K, Wu Y, Kondo T, Kagaya T, Kaneko S, et al. Blocking TNF-α in mice reduces colorectal carcinogenesis associated with chronic colitis. J Clin Invest. 2008;118:560–70.PubMedCentralPubMed
36.
Hale LP, Greer PK. A novel murine model of inflammatory bowel disease and inflammation-associated Colon cancer with ulcerative colitis-like features. PLoS One. 2012;7:e41797.CrossRefPubMedCentralPubMed
37.
Blatner NR, Mulcahy MF, Dennis KL, Scholtens D, Bentrem DJ, Phillips JD, et al. Expression of RORγt marks a pathogenic regulatory T cell subset in human colon cancer. Sci Trans Med. 2012;4:164ra159.CrossRef
38.
Greten FR, Eckmann L, Greten TF, Park JM, Li Z, Egan LJ, et al. IKK-beta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell. 2004;118:285–96.CrossRefPubMed
39.
Shaked H, Hofseth LJ, Chumanevich A, Chumanevich AA, Wang J, Wang Y. Chronic epithelial NF-κB activation accelerates APC loss and intestinal tumor initiation through iNOS up-regulation. Proc Natl Acad Sci. 2012;109:14007–12.CrossRefPubMedCentralPubMed
40.
Koliaraki V, Pasparakis M, Kollias G. IKKβ in intestinal mesenchymal cells promotes initiation of colitis-associated cancer. J Exp Med. 2015;212:2235–51.CrossRefPubMedCentralPubMed
41.
Grivennikov S, Karin E, Terzic J, Mucida D, Yu G, Vallabhapurapu S, et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell. 2009;15:103–13.CrossRefPubMedCentralPubMed
42.
Baltgalvis KA, Berger FG, Pena MMO, Davis JM, Muga SJ, Carson JA, et al. Interleukin-6 and cachexia in Apc min /+ mice. Am J Physiol Regul Integr Comp Physiol. 2008;294:393–401.CrossRef
43.
Bollrath J, Phesse TJ, Von Burstin VA, Putoczki T, Bennecke M, Bateman T, et al. Article gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell. 2009;15:91–102.CrossRefPubMed
44.
Musteanu M, Blaas L, Mair M, Schlederer M, Bilban M, Tauber S, et al. Stat3 is a negative regulator of intestinal tumor progression in ApcMin mice. Gastroenterology. 2010;138:1003–1011.e5.CrossRefPubMed
45.
Pathria P, Gotthardt D, Prchal-Murphy M, Putz E-M, Holcmann M, Schlederer M, et al. Myeloid STAT3 promotes formation of colitis-associated colorectal cancer in mice. Oncoimmunology. 2015;4:e998529.CrossRefPubMedCentralPubMed
46.
Putoczki TL, Thiem S, Loving A, Busuttil RA, Wilson NJ, Ziegler PK, et al. Interleukin-11 is the dominant IL-6 family cytokine during Gastrointestinal tumorigenesis and can be targeted therapeutically. Cancer Cell. 2013;24:257–71.CrossRefPubMed
47.
Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E, et al. Suppression of intestinal polyposis in Apc-delta 716 knockout mice by inhibition of cyclooxygenase 2 ( COX-2). Cell. 1996;87:803–9.CrossRefPubMed
48.
Chulada PC, Thompson MB, Mahler JF, Doyle CM, Gaul BW, Lee C, et al. Genetic disruption of Ptgs-1, as well as of Ptgs-2, reduces intestinal tumorigenesis in min mice. Cancer Res. 2000;60:4705–8.PubMed
49.
Groden J, Thliveris A, Samowitz W, Carlson M, Gelbert L, Albertsen H, et al. Identification and characterization of the familial adenomatous polyposis coli gene. Cell. 1991;66:589–600.CrossRefPubMed
50.
51.
The Cancer Genome Atlas Network. Comprehesive molecular characterization of human colon and rectal cancer. Nature. 2012;487:330–7.CrossRefPubMedCentral
52.
Rapaich A, Pitot HC, Dove WF, Moser AMYR, Pitot HC, Dove WF. A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse published by: American Association for the Advancement of Science Stable URL: http://​www.​jstor.​org/​stable/​2873632 A dominant mutation that predisposes to multiple intesti. 1990;247:322–4.
53.
Stanilov NS, Miteva L, Cirovski G, Stanilova SA. Increased transforming growth factor β and interleukin 10 transcripts in peripheral blood mononuclear cells of colorectal cancer patients. Contemp Oncol. 2016;20:458–62.
54.
Glocker E-O, Kotlarz D, Boztug K, Gertz EM, Schäffer AA, Noyan F, et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med. 2009;361:2033–45.CrossRefPubMedCentralPubMed
55.
• Chung AY, Li Q, Blair SJ, De Jesus M, Dennis KL, Levea C, et al. Oral interleukin-10 alleviates polyposis via neutralization of pathogenic T-regulatory cells. Cancer Res. 2014;74:5377–85. Showed that oral IL-10 administration can downregulate pathogenic Th17 response in order to reduce tumor size and incidence. CrossRefPubMedCentralPubMed
56.
Parker BS, Rautela J, Hertzog PJ. Review. Antitumour actions of interferons: implications for cancer therapy. Nature rev. Cancer. 2016;16:131–44.PubMed
57.
58.
De Simone V, Pallone F, Monteleone G, De Simone V, Pallone F, Monteleone G, et al. Role of T H 17 cytokines in the control of colorectal cancer. Oncoimmunology. 2013;2(12):e26617.CrossRefPubMedCentralPubMed
59.
60.
Wu P, Wu D, Ni C, Ye J, Chen W, Hu G, et al. ydT17 cells promote the accumulation and expansion of myeloid-derived suppressor cells in human colorectal cancer. Immunity. 2014;40:785–800.CrossRefPubMedCentralPubMed
61.
Heikkila K, Ebrahim S, Lawlor DA. Systematic review of the association between circulating interleukin-6 (IL-6) and cancer. Eur J Cancer. 2008;44:937–45.CrossRefPubMed
62.
Olsen J, Kirkeby LT, Olsen J, Eiholm S, Jess PER, Gögenur I, et al. High interleukin-6 mRNA expression is a predictor of relapse in colon cancer. Anticancer Res. 2015;2240:2235–40.
63.
Zhou L, Ivanov II, Spolski R, Min R, Shenderov K, Egawa T, et al. IL-6 programs TH-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol. 2007;8:967–74.CrossRefPubMed
64.
65.
Sanchez-Lopez E, Flashner-Abramson E, Shalapour S, Zhong Z, Taniguchi K, Levitzki A, et al. Targeting colorectal cancer via its microenvironment by inhibiting IGF-1 receptor-insulin receptor substrate and STAT3 signaling. Oncogene. 2015;35:1–11.
66.
• Kryczek I, Lin Y, Nagarsheth N, Peng D, Zhao L, Zhao E, et al. Stemness via STAT3 transcription factor activation and induction of the methyltransferase DOT1L. Immunity. 2013;40:772–84. Demonstrates a role for STAT3 signaling, in order to upregulate stemness genes through DOTL1, a methyltransferase. CrossRef
67.
De Simone V, Franzè E, Ronchetti G, Colantoni A, Fantini MC, Di Fusco D, et al. Th17-type cytokines, IL-6 and TNF-α synergistically activate STAT3 and NF-kB to promote colorectal cancer cell growth. Oncogene. 2015;34:3493–503.CrossRefPubMed
68.
Ben-Neriah Y, Karin M. Review. Inflammation meets cancer, with NF-κB as the matchmaker. Nat. Immunol. 2011;12:715–23.
69.
Nenci A, Becker C, Wullaert A, Gareus R, Van Loo G, Danese S, et al. Epithelial NEMO links innate immunity to chronic intestinal inflammation. Nature. 2007;446:557–61.CrossRefPubMed
70.
• Cooks T, Pateras IS, Tarcic O, Solomon H, Schetter AJ, Wilder S, et al. Mutant p53 prolongs NF-κB activation and promotes chronic inflammation and inflammation-associated colorectal cancer. Cancer Cell. 2013;23:634–46. Demonstrates that in mutant p53 had oncogenic functions in chronic colitis via NF-κB signaling, in order to promote invasive carcinoma. CrossRefPubMedCentralPubMed
71.
Oshima H, Hioki K, Popivanova BK, Van Rooijen N, Ishikawa TO, Oshima M. Prostaglandin E2 signaling and bacterial infection recruit tumor-promoting macrophages to mouse gastric tumors. Gastroenterology. 2011;140:596–607.CrossRefPubMed
72.
Zelenay S, Van Der Veen AG, Bottcher JP, Snelgrove KJ, Rogers N, Acton SE, et al. Cyclooxygenase-dependent tumor growth through evasion of immunity. Cell. 2015;162:1257–70.CrossRefPubMedCentralPubMed
73.
Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372:2509–20.CrossRefPubMedCentralPubMed
74.
Garza-Treviño EN, Said-Fernández SL, Martínez-Rodríguez HG. Understanding the colon cancer stem cells and perspectives on treatment. Cancer Cell Int. 2015;15:2.CrossRefPubMedCentralPubMed
75.
Diehn M, Cho RW, Lobo NA, Kalisky T, Jo M, Kulp AN, et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature. 2009;458:780–3.CrossRefPubMedCentralPubMed
76.
O’Brien CA, Kreso A, Ryan P, Hermans KG, Gibson L, Wang Y, et al. ID1 and ID3 regulate the self-renewal capacity of human colon cancer-initiating cells through p21. Cancer Cell. 2012;21:777–92.CrossRefPubMed
77.
Ibrahem S, Al-Ghamdi S, Baloch K, Muhammad B, Fadhil W, Jackson D, et al. STAT3 paradoxically stimulates beta-catenin expression but inhibits beta-catenin function. Int J Exp Pathol. 2014;95:392–400.
78.
Lin L, Liu A, Peng Z, Lin HJ, Li PK, Li C, et al. STAT3 is necessary for proliferation and survival in colon cancer-initiating cells. Cancer Res. 2011;71:7226–37.CrossRefPubMedCentralPubMed
79.
Spitzner M, Roesler B, Bielfeld C, Emons G, Gaedcke J, Wolff HA, et al. STAT3 inhibition sensitizes colorectal cancer to chemoradiotherapy in vitro and in vivo. Int J Cancer. 2014;134:997–1007.CrossRefPubMed
80.
Phesse TJ, Buchert M, Stuart E, Flanagan DJ, Faux M, Afshar-Sterle S, et al. Partial inhibition of gp130-Jak-Stat3 signaling prevents Wnt-β-catenin-mediated intestinal tumor growth and regeneration. Sci Signal. 2014;7:ra92.
81.
Lindemans CA, Calafiore M, Mertelsmann AM, O’Connor MH, Dudakov JA, Jenq RR, et al. Interleukin-22 promotes intestinal-stem-cell-mediated epithelial regeneration. Nature. 2015;528:560–4.CrossRefPubMedCentralPubMed
82.
Schwitalla S, Fingerle AA, Cammareri P, Nebelsiek T, Göktuna SI, Ziegler PK, et al. Intestinal tumorigenesis initiated by dedifferentiation and acquisition of stem-cell-like properties. Cell. 2013;152:25–38.CrossRefPubMed
83.
Myant KB, Cammareri P, McGhee EJ, Ridgway RA, Huels DJ, Cordero JB, et al. ROS production and NF-kappaB activation triggered by RAC1 facilitate WNT-driven intestinal stem cell proliferation and colorectal cancer initiation. Cell Stem Cell. 2013;12:761–73.CrossRefPubMedCentralPubMed
84.
Du Q, Geller DA. Cross-regulation between Wnt and NF-kB signaling pathways. Immunopathol Dis Ther. 2011;1:1–18.
85.
Clevers HC, Bevins CL. Paneth cells: maestros of the small intestinal crypts. Annu Rev Physiol. 2013;75:289–311.CrossRefPubMed
86.
Adolph TE, Tomczak MF, Niederreiter L, Ko H-J, Bock J, Martinez-naves E, et al. Paneth cells as a site of origin for intestinal inflammation. Nature. 2013;503:272–6.PubMedCentralPubMed
87.
• Feng Y, Sentani K, Wiese A, Sands E, Green M, Bommer GT, et al. Sox9 induction, ectopic paneth cells, and mitotic spindle axis defects in mouse colon adenomatous epithelium arising from conditional biallelic Apc inactivation. Am J Pathol. 2013;183:493–503. Describes ectopic Paneth cell expression driven by Apc inactivation in Cdx2-CreER(T2) model of colon tumorigenesis. CrossRefPubMedCentralPubMed
88.
Joo M, Shahsafaei A, Odze RD. Paneth cell differentiation in colonic epithelial neoplasms: evidence for the role of the Apc/beta-catenin/Tcf pathway. Hum Pathol. 2009;40:872–80.CrossRefPubMed
89.
Wada R. Proposal of a new hypothesis on the development of colorectal epithelial neoplasia: nonspecific inflammation-colorectal Paneth cell metaplasia-colorectal epithelial neoplasia. Digestion. 2009;79:9–12.CrossRefPubMed
90.
Wang D, Peregrina K, Dhima E, Lin EY, Mariadason JM, Augenlicht LH. Paneth cell marker expression in intestinal villi and colon crypts characterizes dietary induced risk for mouse sporadic intestinal cancer. Proc Natl Acad Sci. 2011;108:10272–7.CrossRefPubMedCentralPubMed
91.
Pai RK, Rybicki LA, Goldblum JR, Shen B, Xiao S-Y, Liu X. Paneth cells in colonic adenomas association with male sex and adenoma burden. Am J Surg Pathol. 2013;37:98–103.CrossRefPubMed
92.
Mahon M, Xu J, Yi X, Liu X, Gao N, Zhang L. Paneth cell in adenomas of the distal colorectum is inversely associated with synchronous advanced adenoma and carcinoma. Sci Rep. 2016;6:26129. doi:10.​1038/​srep26129.
93.
• Hilkens J, Timmer NC, Boer M, Ikink GJ, Schewe M, Sacchetti A, et al. RSPO3 expands intestinal stem cell and niche compartments and drives tumorigenesis. Gut. 2016;66:1095–105. Describes overexpression of R-spondin 3 (RSPO3) in a subset of CRCs and uses a mouse model of conditional Rspo3 expression driven by Lgr5-GFP-CreER(T2) to demonstrate up-regulation of intestinal stem and Paneth cells as well as adenocarcinoma.
94.
• Nakanishi Y, Reina-Campos M, Nakanishi N, Llado V, Elmen L, Peterson S, et al. Control of Paneth cell fate, intestinal inflammation, and tumorigenesis by PKCλ/Ι. Cell Rep. 2016;16:3297–310. Highlights the role of protein kinase C (PKC) λ/ι in Paneth cell homeostasis, intestinal inflammation, and cancer. CrossRefPubMedCentralPubMed
95.
Fujii M, Shimokawa M, Date S, Takano A, Matano M, Nanki K, et al. A colorectal tumor organoid library demonstrates progressive loss of niche factor requirements during tumorigenesis. Cell Stem Cell. 2016;18:827–38.CrossRefPubMed
96.
97.
Sato T, Vries RG, Snippert HJ, van de Wetering M, Barker N, Stange DE, et al. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature. 2009;459:262–5.CrossRefPubMed
98.
Van De Wetering M, Francies HE, Francis JM, Bounova G, Iorio F, Pronk A, et al. Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell. 2015;161:933–45.CrossRefPubMed
99.
100.
Drost J, van Jaarsveld RH, Ponsioen B, Zimberlin C, van Boxtel R, Buijs A, et al. Sequential cancer mutations in cultured human intestinal stem cells. Nature. 2015;521:43–7.CrossRefPubMed
101.
Barrett CW, Reddy VK, Short SP, Motley AK, Lintel MK, Bradley AM, et al. Selenoprotein P influences colitis-induced tumorigenesis by mediating stemness and oxidative damage. J Clin Invest. 2015;125:2646–60.
102.
Kiraly O, Gong G, Olipitz W, Muthupalani S, Engelward BP. Inflammation-induced cell proliferation potentiates DNA damage-induced mutations in vivo. PLoS Genet. 2015;11:e1004901.CrossRefPubMedCentralPubMed
103.
• Nozaki K, Mochizuki W, Matsumoto Y, Matsumoto T, Fukuda M, Mizutani T, et al. Co-culture with intestinal epithelial organoids allows efficient expansion and motility analysis of intraepithelial lymphocytes. J Gastroenterol. 2016;51:206–13. Describes co-culture of intestinal epithelial organoids with intraepithelial lymphocytes (IELs). CrossRefPubMedCentralPubMed
104.
Pastuła A, Middelhoff M, Brandtner A, Tobiasch M, Höhl B, Nuber AH, et al. Three-dimensional Gastrointestinal organoid culture in combination with nerves or fibroblasts: a method to characterize the Gastrointestinal stem cell niche. Stem Cells Int. 2016;2016:3710836.PubMed
105.
Rogoz A, Reis BS, Karssemeijer RA, Mucida D. A 3-D enteroid-based model to study T-cell and epithelial cell interaction. J Immunol Methods. 2015;421:89–95.CrossRefPubMedCentralPubMed
106.
Shaffiey SA, Jia H, Keane T, Costello C, Wasserman D, Quidgley M, et al. Intestinal stem cell growth and differentiation on a tubular scaffold with evaluation in small and large animals. Regen Med. 2015;11:rme.15.70.
Metadata
Title
Inflammation and Colorectal Cancer
Authors
Apple G. Long
Emma T. Lundsmith
Kathryn E. Hamilton
Publication date
01-08-2017
Publisher
Springer US
Published in
Current Colorectal Cancer Reports / Issue 4/2017
Print ISSN: 1556-3790
Electronic ISSN: 1556-3804
DOI
https://doi.org/10.1007/s11888-017-0373-6

Other articles of this Issue 4/2017

Current Colorectal Cancer Reports 4/2017 Go to the issue

Radiation Therapy and Radiation Therapy Innovations in Colorectal Cancer (JY Wo, Section Editor)

Biomarkers that Predict Response to Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer

Genetic Syndromes, Screening, and Surveillance in Colorectal Cancer (N Kubiliun, Section Editor)

The Role of CT Colonography as a Screening Tool for Colorectal Cancer

Genetic Syndromes, Screening, and Surveillance in Colorectal Cancer (N Kubiliun, Section Editor)

Colorectal Cancer Surveillance: What Is the Optimal Frequency of Follow-up and Which Tools Best Predict Recurrence?

Genetic Syndromes, Screening, and Surveillance in Colorectal Cancer (N Kubiliun, Section Editor)

Quality Colorectal Cancer Screening: Endoscopic Performance Measures and Beyond

Genetic Syndromes, Screening, and Surveillance in Colorectal Cancer (N Kubiliun, Section Editor)

Colonoscopy and Flexible Sigmoidoscopy in Colorectal Cancer Screening and Surveillance

Radiation Therapy and Radiation Therapy Innovations in Colorectal Cancer (JY Wo, Section Editor)

Clinical Target Volume Definition in Preoperative Radiotherapy of Rectal Carcinoma: a Systematic Review
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits